Philadelphia Investment Partners LLC Purchases New Stake in Axsome Therapeutics, Inc. $AXSM

Posted by Brian Himes on Aug 27th, 2026

Philadelphia Investment Partners LLC acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 2,526 shares of the company’s stock, valued at approximately $619,000.

Other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after acquiring an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp increased its position in Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after buying an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after buying an additional 84,151 shares during the last quarter. Caxton Associates LLP bought a new stake in shares of Axsome Therapeutics in the first quarter valued at $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after buying an additional 17,250 shares during the period. Institutional investors own 81.49% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on AXSM shares. HC Wainwright reissued a “buy” rating on shares of Axsome Therapeutics in a report on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 price objective on shares of Axsome Therapeutics in a report on Thursday, June 11th. Truist Financial upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Wells Fargo & Company lifted their target price on shares of Axsome Therapeutics from $255.00 to $256.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Finally, Royal Bank Of Canada lowered their price target on shares of Axsome Therapeutics from $304.00 to $297.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and an average price target of $267.60.

Read Our Latest Stock Report on Axsome Therapeutics

Insider Transactions at Axsome Therapeutics

In related news, Director Susan Mahony sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total transaction of $71,163.00. Following the sale, the director owned 1,129 shares of the company’s stock, valued at approximately $267,810.09. This represents a 20.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Herriot Tabuteau sold 4,660 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $213.95, for a total transaction of $997,007.00. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $1,546,644.55. This trade represents a 39.20% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 200,766 shares of company stock valued at $46,685,646. Company insiders own 20.60% of the company’s stock.

Axsome Therapeutics News Roundup

Here are the key news stories impacting Axsome Therapeutics this week:

Positive Sentiment: HC Wainwright maintained its Buy rating on Axsome Therapeutics, signaling continued confidence in the company’s long-term commercial outlook despite lowering its earnings forecasts.
Neutral Sentiment: The firm continues to project a significant improvement in profitability in 2027, with positive earnings expected beginning in the second quarter and full-year 2027 EPS forecast at $5.25.
Neutral Sentiment: A report showing zero short interest as of August 25 does not indicate meaningful short-selling pressure, although the data appears inconsistent because it also reports no change from the prior period.
Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $4.10 from a loss of $3.89, while cutting forecasts for third-quarter and fourth-quarter 2026 EPS to losses of $0.95 and $0.91, respectively.
Negative Sentiment: The analyst also lowered its 2027 estimates: first-quarter EPS was revised to a $0.27 loss from $0.05 in earnings, second-quarter EPS to $1.06 from $1.30, third-quarter EPS to $1.92 from $2.30, and full-year EPS to $5.25 from $6.47. Fourth-quarter 2027 EPS was reduced to $2.53 from $2.81.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $207.15 on Thursday. Axsome Therapeutics, Inc. has a 52-week low of $112.90 and a 52-week high of $260.19. The stock’s 50-day simple moving average is $229.34 and its 200 day simple moving average is $206.61. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. The stock has a market capitalization of $10.85 billion, a price-to-earnings ratio of -55.24 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The company had revenue of $218.38 million for the quarter, compared to analysts’ expectations of $221.11 million. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.8 EPS for the current fiscal year.

Axsome Therapeutics Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.